Tiantan Biological Products issued an announcement, expecting net profit attributable to the parent for the first half of 2026 to be 305 million yuan, a year-on-year decline of about 51.75 percent. It expects net profit attributable to the parent after deducting non-recurring items to be 291 million yuan, a year-on-year decrease of about 52.89 percent. The company said the expected decline in performance is mainly due to factors such as medical insurance cost control and payment method reforms since the second half of 2024, which have intensified competition in the blood products industry and led to a downward trend in product sales prices. At the same time, the adjustment of value-added tax policies for biological products implemented from January 1, 2026, also had a negative impact on operating performance in the first half of the year. In the first quarter of 2026, Tiantan Biological Products achieved revenue of 1.142 billion yuan and net profit attributable to the parent of 126 million yuan.
Beijing Tiantan Biological Products Corp LtdCompany expects net profit to fall 51.75% due to downward trend in product sales prices from medical insurance cost control and VAT policy adjustment.